Summary

Lyme Disease Testing Market Growth & Trends

The global lyme disease testing market size is anticipated to reach USD 18.57 billion by 2030 and is projected to grow at a CAGR of 8.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The primary factors driving this market are the increasing prevalence, supportive government policies regarding healthcare facilities, and the introduction of new diagnostic tests for Lyme disease. In addition, the growing incidence of tick-borne diseases further expands the global market. For instance, in August 2022, the U.S. Fair Health Organization reported that Lyme disease has significantly increased in prevalence over the past 15 years, becoming a growing national concern.

Growing government initiatives and preventive measures significantly drive the market growth. For instance, in July 2022, an article titled "New laws seek to boost funding of Lyme disease research" highlighted that New York officials have increased funding for Lyme disease and tick-borne illnesses through a new law signed by Governor Kathy Hochul. This bipartisan measure will establish a voluntary tax check-off box to support education, research, and prevention efforts related to the disease in the region. Despite the high incidence of Lyme and tick-borne illnesses, it is believed that the actual number of cases is much higher due to inaccurate diagnostic testing.

Heightened awareness and education are further propelling market growth. Public health campaigns to educate communities about prevention strategies and symptoms have become increasingly prevalent. This growing awareness leads to more individuals seeking medical attention when they exhibit symptoms consistent with the disease, thereby driving demand for reliable testing options. Furthermore, educational initiatives targeting healthcare professionals ensure they remain informed about best practices for diagnosis and treatment.

Lyme Disease Testing Market Report Highlights

• Based on technology, the other segment led the market with the largest revenue share of 88.6% in 2023. The widespread adoption of these tests, considered the gold standard for testing due to their high specificity and sensitivity, significantly contributed to the growth of this segment

• Based on testing, the serological test segment led the market with the largest revenue share of 53.1% in 2023. These tests dominated the market as they are widely available, affordable, established, and reliable in detecting antibodies against Borrelia burgdorferi. This makes them a trusted and accessible option for healthcare providers and patients

• Based on sample, the blood segment led the market with the largest revenue share of 62.4% in 2023. This is due to the blood tests, such as ELISA and Western blot, which can effectively detect antibodies against Borrelia burgdorferi, the bacteria causing Lyme disease. Blood samples are also easy to obtain and handle, making them a practical choice for widespread diagnostic use

• Based on end use, the hospital segment led the market with the largest revenue share of 58.4% in 2023. Firstly, hospitals can access advanced technology and diagnostic tools, enabling accurate & timely testing. The high hospital patient volume, including those with complex and severe symptoms, necessitates reliable diagnostic services, further driving their market dominance

• In January 2024, DiaSorin announced that it submitted the LIAISON LymeDetect test to the U.S. FDA in December 2023. Developed in partnership with QIAGEN, this test detects IgG, IgM, and T-cell mediated responses using QIAGEN’s proprietary QuantiFERON technology, an Interferon-Gamma Release Assay (IGRA). This novel solution will enhance DiaSorin's LIAISON immunodiagnostic offerings in the U.S. market, representing a significant milestone in its collaboration with QIAGEN

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Technology
1.2.2. Testing
1.2.3. Sample
1.2.4. End Use
1.2.5. Regional scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Technology outlook
2.2.2. Testing outlook
2.2.3. Sample outlook
2.2.4. End Use outlook
2.2.5. Regional outlook
2.3. Competitive Insights
Chapter 3. Lyme Disease Testing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Rise in prevalence of lyme disease
3.2.1.2. Rising number of research programs for Lyme disease diagnosis
3.2.1.3. Launch of new lyme diagnostic tests
3.2.2. Market restraint analysis
3.2.2.1. Lack of awareness regarding testing
3.3. Lyme Disease Testing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pipeline Analysis
Chapter 4. Lyme Disease Testing Market: Technology Estimates & Trend Analysis
4.1. Global Lyme Disease Testing Market: Technology Dashboard
4.2. Global Lyme Disease Testing Market: Technology Movement Analysis
4.3. Global Lyme Disease Testing Market by Technology, Revenue
4.4. IGRA Testing
4.4.1. IGRA Testing market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Others
4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Lyme Disease Testing Market: Testing Estimates & Trend Analysis
5.1. Global Lyme Disease Testing Market: Testing Dashboard
5.2. Global Lyme Disease Testing Market: Testing Movement Analysis
5.3. Global Lyme Disease Testing Market Estimates and Forecasts, by Testing, Revenue (USD Million)
5.4. Serological Test
5.4.1. Serological Test market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. ELISA
5.4.2.1. ELISA market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. Western Blot
5.4.3.1. Western blot market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Lymphocytic Transformation Test
5.5.1. Lymphocytic transformation test market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Urine Antigen Testing
5.6.1. Urine Antigen Testing market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Immunofluorescent Staining
5.7.1. Immunofluorescent Staining market estimates and forecasts 2018 to 2030 (USD Million)
5.8. Nucleic Acid Test
5.8.1. Nucleic Acid Test market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Lyme Disease Testing Market: Sample Estimates & Trend Analysis
6.1. Global Lyme Disease Testing Market: Sample Dashboard
6.2. Global Lyme Disease Testing Market: Sample Movement Analysis
6.3. Global Lyme Disease Testing Market Estimates and Forecasts, By Sample, Revenue (USD Million)
6.4. Blood
6.4.1. Blood market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Urine
6.5.1. Urine market estimates and forecasts 2018 to 2030 (USD Million)
6.6. CSF
6.6.1. CSF market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Others
6.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Lyme Disease Testing Market: End Use Estimates & Trend Analysis
7.1. Global Lyme Disease Testing Market: End Use Dashboard
7.2. Global Lyme Disease Testing Market: End Use Movement Analysis
7.3. Global Lyme Disease Testing Market Estimates and Forecasts, By End Use, Revenue (USD Million)
7.4. Hospitals
7.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Diagnostic Laboratories
7.5.1. Diagnostic Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Others
7.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Lyme Disease Testing Market: Regional Estimates & Trend Analysis by Technology, Sample, Testing, and End Use
8.1. Regional Dashboard
8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
8.3. North America
8.3.1. U.S.
8.3.1.1. Key country dynamics
8.3.1.2. Regulatory framework/ reimbursement structure
8.3.1.3. Competitive scenario
8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
8.3.2. Canada
8.3.2.1. Key country dynamics
8.3.2.2. Regulatory framework/ reimbursement structure
8.3.2.3. Competitive scenario
8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
8.3.3. Mexico
8.3.3.1. Key country dynamics
8.3.3.2. Regulatory framework/ reimbursement structure
8.3.3.3. Competitive scenario
8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
8.4. Europe
8.4.1. UK
8.4.1.1. Key country dynamics
8.4.1.2. Regulatory framework/ reimbursement structure
8.4.1.3. Competitive scenario
8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
8.4.2. Germany
8.4.2.1. Key country dynamics
8.4.2.2. Regulatory framework/ reimbursement structure
8.4.2.3. Competitive scenario
8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
8.4.3. France
8.4.3.1. Key country dynamics
8.4.3.2. Regulatory framework/ reimbursement structure
8.4.3.3. Competitive scenario
8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
8.4.4. Italy
8.4.4.1. Key country dynamics
8.4.4.2. Regulatory framework/ reimbursement structure
8.4.4.3. Competitive scenario
8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
8.4.5. Spain
8.4.5.1. Key country dynamics
8.4.5.2. Regulatory framework/ reimbursement structure
8.4.5.3. Competitive scenario
8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
8.4.6. Norway
8.4.6.1. Key country dynamics
8.4.6.2. Regulatory framework/ reimbursement structure
8.4.6.3. Competitive scenario
8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
8.4.7. Sweden
8.4.7.1. Key country dynamics
8.4.7.2. Regulatory framework/ reimbursement structure
8.4.7.3. Competitive scenario
8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
8.4.8. Denmark
8.4.8.1. Key country dynamics
8.4.8.2. Regulatory framework/ reimbursement structure
8.4.8.3. Competitive scenario
8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework/ reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
8.5.2. China
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework/ reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
8.5.3. India
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework/ reimbursement structure
8.5.3.3. Competitive scenario
8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
8.5.4. Australia
8.5.4.1. Key country dynamics
8.5.4.2. Regulatory framework/ reimbursement structure
8.5.4.3. Competitive scenario
8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
8.5.5. South Korea
8.5.5.1. Key country dynamics
8.5.5.2. Regulatory framework/ reimbursement structure
8.5.5.3. Competitive scenario
8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
8.5.6. Thailand
8.5.6.1. Key country dynamics
8.5.6.2. Regulatory framework/ reimbursement structure
8.5.6.3. Competitive scenario
8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/ reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
8.6.2. Argentina
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
8.7. MEA
8.7.1. South Africa
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/ reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
8.7.2. Saudi Arabia
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
8.7.3. UAE
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/ reimbursement structure
8.7.3.3. Competitive scenario
8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
8.7.4. Kuwait
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/ reimbursement structure
8.7.4.3. Competitive scenario
8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company/Competition Categorization
9.2. Vendor Landscape
9.2.1. List of key distributors and channel partners
9.2.2. Key customers
9.2.3. Key company market share analysis, 2023
9.2.4. DiaSorin S.p.A
9.2.4.1. Company overview
9.2.4.2. Financial performance
9.2.4.3. Product benchmarking
9.2.4.4. Strategic initiatives
9.2.5. BIOMÉRIEUX
9.2.5.1. Company overview
9.2.5.2. Financial performance
9.2.5.3. Product benchmarking
9.2.5.4. Strategic initiatives
9.2.6. Oxford Immunotec
9.2.6.1. Company overview
9.2.6.2. Financial performance
9.2.6.3. Product benchmarking
9.2.6.4. Strategic initiatives
9.2.7. Bio-Rad Laboratories, Inc.
9.2.7.1. Company overview
9.2.7.2. Financial performance
9.2.7.3. Product benchmarking
9.2.7.4. Strategic initiatives
9.2.8. Thermo Fisher Scientific, Inc.
9.2.8.1. Company overview
9.2.8.2. Financial performance
9.2.8.3. Product benchmarking
9.2.8.4. Strategic initiatives
9.2.9. T2 Biosystems
9.2.9.1. Company overview
9.2.9.2. Financial performance
9.2.9.3. Product benchmarking
9.2.9.4. Strategic initiatives
9.2.10. IGeneX
9.2.10.1. Company overview
9.2.10.2. Financial performance
9.2.10.3. Product benchmarking
9.2.10.4. Strategic initiatives
9.2.11. Gold Standard Diagnostics
9.2.11.1. Company overview
9.2.11.2. Financial performance
9.2.11.3. Product benchmarking
9.2.11.4. Strategic initiatives
9.2.12. ZEUS Scientific
9.2.12.1. Company overview
9.2.12.2. Financial performance
9.2.12.3. Product benchmarking
9.2.12.4. Strategic initiatives
9.2.13. Trinity Biotech
9.2.13.1. Company overview
9.2.13.2. Financial performance
9.2.13.3. Product benchmarking
9.2.13.4. Strategic initiatives